180 related articles for article (PubMed ID: 28728452)
1. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
Schmitt NC; Page BR
Int J Audiol; 2018 Sep; 57(sup4):S49-S54. PubMed ID: 28728452
[TBL] [Abstract][Full Text] [Related]
2. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Das N; Kaushal D; Patro SK; Pareek P; Dixit A; Soni K; Prakasan Nair N; Choudhury B; Goyal A
Acta Otolaryngol; 2021 Sep; 141(9):885-893. PubMed ID: 34486907
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
4. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
5. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature.
Theunissen EA; Bosma SC; Zuur CL; Spijker R; van der Baan S; Dreschler WA; de Boer JP; Balm AJ; Rasch CR
Head Neck; 2015 Feb; 37(2):281-92. PubMed ID: 24478269
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
7. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
9. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
10. Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B; Knight K
Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
Ishikawa E; Sugimoto H; Hatano M; Nakanishi Y; Tsuji A; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
Acta Otolaryngol; 2015 Sep; 135(9):919-24. PubMed ID: 25861690
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Ameri A; Norouzi S; Sourati A; Azghandi S; Novin K; Taghizadeh-Hesary F
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1425. PubMed ID: 34101389
[TBL] [Abstract][Full Text] [Related]
14. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
Schuette A; Lander DP; Kallogjeri D; Collopy C; Goddu S; Wildes TM; Daly M; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):106-112. PubMed ID: 31750863
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
Liao XB; Yan SX
Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
[No Abstract] [Full Text] [Related]
16. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
[TBL] [Abstract][Full Text] [Related]
17. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
Mahdavi SR; Rezaeyan A; Nikoofar A; Bakhshandeh M; Farahani S; Cheraghi S
J Cancer Res Ther; 2020; 16(3):539-545. PubMed ID: 32719264
[TBL] [Abstract][Full Text] [Related]
18. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction after intra-arterial chemotherapy for hypopharyngeal and laryngeal cancer.
Endo K; Masatani T; Tsuji A; Kondo S; Wakisaka N; Murono S; Yoshizaki T
Auris Nasus Larynx; 2015 Jun; 42(3):231-4. PubMed ID: 25544714
[TBL] [Abstract][Full Text] [Related]
20. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
